World Federation of Hemophilia is replaced by CSL Behring, a factor IX-donation on World Hemophilia Day

KING OF PRUSSIA, Pennsylvania, and MONTREAL, April 17, 2010 (ots / PRNewswire) - The recently developed by CSL Behring to the World Federation of Hemophilia (WFH) made donation of 1 million international units of Factor IX Hemophilia B is drug- patients in developing countries benefit. The donation was made to the National Association of WFH in the United Kingdom in order to emphasize the importance of the World Hemophilia tags 2010 and the progress of the initiative Global Alliance for Progress (CAP) of the WFH in the diagnosis and treatment of hemophilia in developing countries . support

The total value of the donation amounts to approximately $ 700,000, in addition to a coagulation factor donation of $ 2 million (over a period of three years), the CSL Behring has made last year to the WFH. The factor IX product of CSL Behring is produced in the establishment of the company in Kankakee, the U.S. state of Illinois. CSL Ltd.., The parent company of CSL Behring, would like to use for the economic, social and environmental well-being of its communities.

CSL Behring has also renewed his promise to provide financial support and the WFH is to leave as a period of three years, provide a total of nearly $ 1 million.

"CSL Behring provides long been his contribution to the CAP initiative and is now proud and pleased to be able to allocate more funds to support the World Federation of Hemophilia," said Peter Turner, President and Chief Executive Officer of CSL Behring. "Like the WFH endeavor we also make improvements and changes in the provision of health services and drugs for patients in regions where there is a high demand. We focus on services for patients with rare and severe hemophilia, and always on the lookout for ways to to effect great and positive changes for themselves and their communities, "said Turner continued.

"Without product donations it would not be the WFH possible, his efforts to fully implement and clotting factor concentrates to make available in developing countries, where they otherwise might not be available," said Mark Skinner, president of the WFH. "These donations in turn may improve the overall treatment offered to needy people with hemophilia. The generous and sustained support from CSL Behring allows the WFH to keep their Organisationsversprechen and help build sustainable, nationwide hemophilia treatment services, which an essential part of the worldwide health care network account. We are all our industry partners who provide us with valuable, life-saving drugs - such as the recent donation of factor IX for the treatment of hemophilia B by CSL Behring - and other resources available, a debt of gratitude, " Sun Skinner on.

Factor IX is an important clotting factor. FIX is a concentrate from donor blood or is produced in a recombinant process. It can be administered to hemophiliacs to cause blood to clot. Tip for stay in Germany

Information about the Global Alliance for Progress
The Global Alliance for Progress (CAP) was launched in 2003 and is a development project for health care, with a maturity of 10 years. The goal of the CAP initiative is to contribute in developing an increased diagnosis and treatment of people with hemophilia and other bleeding disorders.

The project aims to fill the gaps between the number of haemophilia born people and those who reach adulthood, between the estimated and actual number of close with bleeding disorders diagnosed patients, and between the amount of required and actually available treatment products.

The CAP project is supported by the following partners: CSL Behring, Baxter, Bayer, Biotest, the Irish Hemophilia Society, the Jan Willem André de la Porte Family Foundation, Pfizer, Talecris and the World Health Organisation (WHO).

Sixteen countries have already participated in the CAP program: Armenia, Azerbaijan, Belarus, China, Ecuador, Egypt, Georgia, Jordan, Lebanon, Mexico, the Philippines, Russia, Syria, Thailand, and Tunisia. Was also recently launched a CAP initiative in Peru to life.

Information on the World Federation of Hemophilia
The World Federation of Hemophilia (WFH) is an international nonprofit organization committed to improving the lives of people with hemophilia and related bleeding disorders.

Since its founding in 1963, the WFH has grown into one of the World Health Organization officially recognized, global network with member organizations in over 113 countries. The WFH is working with experts from the health care industry, hemophilia, governments and public authorities, industry and foundations, to improve hemophilia care worldwide. For more information, visit

About CSL Behring
CSL Behring is a global leader in plasma protein biotherapeutics industry. The company manufactures and markets a range of plasma and recombination therapies and is committed to improving the lives of patients with rare and serious diseases.

The CSL Behring therapies are used in the treatment of clotting disorders such as hemophilia, the von Willebrand Disease, primary immunodeficiency diseases, congenital hereditary angioedema and respiratory diseases on the application. The company's products in cardiac surgery, organ transplantation, used to treat burns and applied to the prevention of hemolytic diseases in newborns.

The company also operates CSL Plasma, one of the world's largest networks for plasma donations. CSL Behring is a subsidiary of CSL Limited, a biopharmaceutical company based in Melbourne (Australia). For more information, visit

Further informations and topics in german can be found here!